Prof Meletios Dimopoulos speaks to ecancer about the results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) compared to VRd for transplant-ineligible patients with newly diagnosed multiple myeloma from the IMROZ study.

The study investigated the efficacy and safety of isatuximab, bortezomib, lenalidomide, and dexamethasone compared to bortezomib, lenalidomide, and dexamethasone in transplant-ineligible NDMM patients.

The results showed a significantly reduced risk of progression or death by 40.4% compared to VRd while providing deep and sustained responses.